This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Fibricor

Aralez Pharmaceuticals Inc.

Drug Names(s): MPC-028, fenofibric acid

Description: Fibricor is a formulation of 35 mg or 105 mg of fenofibrate (105 mg is equivalent to 145 mg TriCor under fasted conditions). It is being marketed as a lower cost alternative. Fenofibrate is a peroxisome proliferator receptor alpha (PPARa) activator.

Deal Structure: Takeda and URL Pharma
In April 2012, Takeda and URL Pharma entered into a definitive agreement where Takeda will acquire URL Pharma for an upfront payment of $800 million and future performance-based contingent earn out payments. Upon completion of the acquisition, URL Pharma will be managed by Takeda. The acquisition closed in June 2012.

Takeda and Sun Pharma
In December 2012, Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A. (TPUSA) entered into a definitive agreement with Caraco, a wholly-owned subsidiary of Sun Pharmaceutical for the sale of the non-Colcrys (colchicine, USP) URL Pharma generic business.

As per the agreement with Caraco, TPUSA will retain ownership of Colcrys and is exclusively responsible for the marketing and promotion of Colcrys. Upon completion of the sale, the non-Colcrys assets of URL Pharma will be owned and managed by Caraco. The deal is subject to satisfaction of customary closing conditions, including...See full deal structure in Biomedtracker


Fibricor News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug